ASLAN Pharmaceuticals Statistics
Share Statistics
ASLAN Pharmaceuticals has 2.83M
shares outstanding. The number of shares has increased by -87.5%
in one year.
| Shares Outstanding | 2.83M |
| Shares Change (YoY) | -87.5% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 3.46% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 995 |
| FTD / Avg. Volume | 0.97% |
Short Selling Information
The latest short interest is 55.57K, so 1.96% of the outstanding
shares have been sold short.
| Short Interest | 55.57K |
| Short % of Shares Out | 1.96% |
| Short % of Float | 2.11% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.55 and the forward
PE ratio is null.
ASLAN Pharmaceuticals's PEG ratio is
0.06.
| PE Ratio | -1.55 |
| Forward PE | n/a |
| PS Ratio | 5.73 |
| Forward PS | n/a |
| PB Ratio | -5.17 |
| P/FCF Ratio | -1.48 |
| PEG Ratio | 0.06 |
Financial Ratio HistoryEnterprise Valuation
ASLAN Pharmaceuticals has an Enterprise Value (EV) of 74.33M.
| EV / Sales | 6.19 |
| EV / EBITDA | -1.71 |
| EV / EBIT | -1.6 |
| EV / FCF | -1.6 |
Financial Position
The company has a current ratio of 1.84,
with a Debt / Equity ratio of -2.02.
| Current Ratio | 1.84 |
| Quick Ratio | 1.84 |
| Debt / Equity | -2.02 |
| Debt / EBITDA | -0.62 |
| Debt / FCF | -0.58 |
| Interest Coverage | -10.11 |
Financial Efficiency
Return on Equity is 332.81% and Return on Invested Capital is -324.03%.
| Return on Equity | 332.81% |
| Return on Assets | -179.56% |
| Return on Invested Capital | -324.03% |
| Revenue Per Employee | $342,857.14 |
| Profits Per Employee | $-1,263,417.26 |
| Employee Count | 35 |
| Asset Turnover | 0.49 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 132.67K |
| Effective Tax Rate | -0.3% |
Stock Price Statistics
The stock price has increased by -84.04% in the
last 52 weeks. The beta is 1.4, so ASLAN Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.4 |
| 52-Week Price Change | -84.04% |
| 50-Day Moving Average | 1.78 |
| 200-Day Moving Average | 4.17 |
| Relative Strength Index (RSI) | 21.61 |
| Average Volume (20 Days) | 102,493 |
Income Statement
In the last 12 months, ASLAN Pharmaceuticals had revenue of 12M
and earned -44.22M
in profits. Earnings per share was -2.69.
| Revenue | 12M |
| Gross Profit | 11.65M |
| Operating Income | -43.74M |
| Net Income | -44.22M |
| EBITDA | -43.39M |
| EBIT | -39.75M |
| Earnings Per Share (EPS) | -2.69 |
Full Income StatementBalance Sheet
The company has 21.25M in cash and 26.83M in
debt, giving a net cash position of -5.57M.
| Cash & Cash Equivalents | 21.25M |
| Total Debt | 26.83M |
| Net Cash | -5.57M |
| Retained Earnings | -321.07M |
| Total Assets | 20.99M |
| Working Capital | 972.05K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -46.36M
and capital expenditures -10.78K, giving a free cash flow of -46.37M.
| Operating Cash Flow | -46.36M |
| Capital Expenditures | -10.78K |
| Free Cash Flow | -46.37M |
| FCF Per Share | -2.82 |
Full Cash Flow StatementMargins
Gross margin is 97.1%, with operating and profit margins of -364.46% and -368.5%.
| Gross Margin | 97.1% |
| Operating Margin | -364.46% |
| Pretax Margin | -367.32% |
| Profit Margin | -368.5% |
| EBITDA Margin | -361.56% |
| EBIT Margin | -364.46% |
| FCF Margin | -386.42% |
